# Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain

> **NCT03854344** · PHASE4 · COMPLETED · sponsor: **University of Kansas Medical Center** · enrollment: 74 (actual)

## Conditions studied

- Pain, Postoperative
- Burns

## Interventions

- **DRUG:** Lidocaine Hydrochloride
- **DRUG:** Liposomal bupivacaine
- **DRUG:** Bupivacaine Hydrochloride

## Key facts

- **NCT ID:** NCT03854344
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-18
- **Primary completion:** 2025-08-06
- **Final completion:** 2025-10-27
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03854344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03854344, "Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03854344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*